JWCA ADVISES INOTEK PHARMACEUTICALS ON ITS $52.0 million Convertible bond offering

Transaction Background

J. Wood Capital Advisors was hired by Inotek to manage its capital structure and raise new capital in an efficient way:

Provided full analysis on Company’s previous Convertible and implications for a new issuance, including:
- Issuer call features
- Investor make-whole provisions
- Execution fees
- Public vs private marketing
Designed the strategey and execution process to meet the Company's objectives:
- Raised significant capital meet Company's operating needs on attractive terms
- Optimized amount of private marketing to maximize capital raise within the constraints of limited float and borrow
Assisted the team with documentation, accounting, and tax review
Provided advice, support and analysis throughout the negotiation and deal preparation proces

RESULTS

The Company executed a successful capital raise:

Net Cash to Balance Sheet of approximately $49mm provided Inotek with critical funding for ongoing development of trabodenoson as a monotherapy and as a fixed-dose combination with latanoprost for the reduction of intraocular pressure